Ebola Treatment Shown to Work on Infected Monkeys

Global Security Newswire Staff
Add to Briefcase
See more stories about...
Global Security Newswire Staff
Aug. 22, 2013, 9:02 a.m.

A new Ebola drug grown from spe­cial to­bacco plants has been shown to cure mon­keys that were already dis­play­ing signs of in­fec­tion by the vir­al hem­or­rhagic fever, the Los Angeles Times re­por­ted on Wed­nes­day.

Oth­er Ebola coun­ter­meas­ures have been shown to work on in­fec­ted an­im­als be­fore they start dis­play­ing symp­toms of the highly vir­u­lent and leth­al dis­ease. However, this is the first time a drug has demon­strated any ef­fect­ive­ness after signs of the vir­us have mani­fes­ted. That is re­garded as a cru­cial cap­ab­il­ity in the event of a real-life dis­ease epi­dem­ic, ac­cord­ing to vir­o­lo­gist Gene Olinger, who works at the Army Med­ic­al Re­search In­sti­tute of In­fec­tious Dis­eases at Fort De­t­rick, Md.

“We’ve pushed the op­por­tun­ity to treat people to the point where they walk in and say, ‘I have a fever,’” said Olinger, co-au­thor of a re­port on the new Ebola drug pub­lished by the Sci­ence Trans­la­tion­al Medi­cine journ­al on Wed­nes­day. “A lot of folks in the field would have thought pro­tect­ing an an­im­al at the time of fever and viremia is too late to have a clin­ic­al be­ne­fit.”

Ebola is one of the most deadly and con­ta­gious dis­eases known to ex­ist in nature. The lack of ad­equate vac­cines and an­ti­dotes for the dis­ease have made it a ser­i­ous worry for biode­fense spe­cial­ists con­cerned about its pos­sible ap­plic­a­tions as a bio­lo­gic­al weapon.

In the re­cent study, sev­en in­fec­ted rhesus mon­keys were ad­min­istered the ex­per­i­ment­al treat­ment MB-003 through their veins once every three days. Three of the mon­keys did not die, res­ult­ing in a stat­ist­ic­ally not­able suc­cess rate of 43 per­cent.

Fort De­t­rick sci­ent­ist and lead study au­thor James Pet­titt said it is prob­able that in a real-life out­break, the drug would be ad­min­istered at a high­er dosage and with great­er fre­quency.

“We think we’ll get bet­ter res­ults,” the re­search­er said.

Grow­ing the drug from spe­cially de­veloped to­bacco leaves is not only less costly than con­ven­tion­al cell-based meth­ods, but also al­lows for large batches of the drug to be pro­duced on fairly short, weeklong sched­ules, ac­cord­ing to the Times art­icle.

Olinger said fur­ther meas­ures will be taken to im­prove MB-003 by adding to it more Ebola an­ti­bod­ies that were dis­covered by a dif­fer­ent group of re­search­ers.

What We're Following See More »
WITH LIVE BLOGGING
Trump Deposition Video Is Online
15 hours ago
STAFF PICKS

The video of Donald Trump's deposition in his case against restaurateur Jeffrey Zakarian is now live. Slate's Jim Newell and Josh Voorhees are live-blogging it while they watch.

Source:
SOUND LEVEL AFFECTED
Debate Commission Admits Issues with Trump’s Mic
16 hours ago
THE LATEST

The Commission on Presidential Debates put out a statement today that gives credence to Donald Trump's claims that he had a bad microphone on Monday night. "Regarding the first debate, there were issues regarding Donald Trump's audio that affected the sound level in the debate hall," read the statement in its entirety.

Source:
TRUMP VS. CHEFS
Trump Deposition Video to Be Released
16 hours ago
THE LATEST

"A video of Donald Trump testifying under oath about his provocative rhetoric about Mexicans and other Latinos is set to go public" as soon as today. "Trump gave the testimony in June at a law office in Washington in connection with one of two lawsuits he filed last year after prominent chefs reacted to the controversy over his remarks by pulling out of plans to open restaurants at his new D.C. hotel. D.C. Superior Court Judge Brian Holeman said in an order issued Thursday evening that fears the testimony might show up in campaign commercials were no basis to keep the public from seeing the video."

Source:
A CANDIDATE TO BE ‘PROUD’ OF
Chicago Tribune Endorses Gary Johnson
19 hours ago
THE LATEST

No matter that his recall of foreign leaders leaves something to be desired, Gary Johnson is the choice of the Chicago Tribune's editorial board. The editors argue that Donald Trump couldn't do the job of president, while hitting Hillary Clinton for "her intent to greatly increase federal spending and taxation, and serious questions about honesty and trust." Which leaves them with Johnson. "Every American who casts a vote for him is standing for principles," they write, "and can be proud of that vote. Yes, proud of a candidate in 2016."

NEVER TRUMP
USA Today Weighs in on Presidential Race for First Time Ever
1 days ago
THE DETAILS

"By all means vote, just not for Donald Trump." That's the message from USA Today editors, who are making the first recommendation on a presidential race in the paper's 34-year history. It's not exactly an endorsement; they make clear that the editorial board "does not have a consensus for a Clinton endorsement." But they state flatly that Donald Trump is, by "unanimous consensus of the editorial board, unfit for the presidency."

Source:
×